Immunocore

About:

Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies.

Website: http://immunocore.com

Twitter/X: immunocore

Top Investors: BlackRock, General Atlantic, Eli Lilly, RTW Investments, Bill & Melinda Gates Foundation

Description:

Immunocore is focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The company’s expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems. Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies.

Total Funding Amount:

$1.16B

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Abingdon, Oxfordshire, United Kingdom

Founded Date:

2008-01-01

Contact Email:

info(AT)immunocore.com

Founders:

Bent Jakobsen, Nick Cross

Number of Employees:

251-500

Last Funding Date:

2024-01-30

IPO Status:

Public

© 2025 bioDAO.ai